Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 21

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 21
---
 3i, LP (the “3i Consent” and, together with the Nomis Bay Consent and the Oramed
Consent, the “Tranche B Consents”), respectively, pursuant to which the Tranche B Noteholders (as defined below) agreed to defer our obligation to make the First Amortization Payment until January 31, 2025. In consideration of such
deferral, and to limit the Tranche B Noteholders’ right to exercise certain secured creditor remedies (including recourse against the assets of SCLX JV, as a grantor under the Security Agreement (as defined in the Tranche B Consents)), SCLX JV
delivered to the Tranche B Noteholders (or their designee) by deposit/withdrawal at custodian with the Depository Trust Company an aggregate of 142,855 Scilex Shares (as defined in, and contemplated pursuant to, the Term Sheet that is an exhibit to
the Tranche B Consents (the “Term Sheet”)) held by SCLX JV, of which 71,428 shares were delivered to Oramed, 20,571 shares were delivered to BPY Limited, 36,571 shares were delivered to Nomis Bay Ltd, and 14,285 shares were delivered to
3i, LP.

In addition, pursuant to the Tranche B Consents, effective as of the latest of (i) the time of execution and delivery of the
Tranche B Consents, (ii) the time of the delivery of the Scilex Shares and (iii) the time of grant of the Royalty and Exclusive Rights (each as defined in, and contemplated pursuant to, the Term Sheet), the Tranche B Noteholders agreed to
further defer our obligation to make the First Amortization Payment until October 8, 2026, provided that, as contemplated in the Term Sheet, we pay an aggregate of $1.1 million in respect of a portion of the First Amortization Payment and
related make-whole interest (which amount has been paid).

The Term Sheet provided that we and the Tranche B Noteholders would enter into
an agreement pursuant to which the Tranche B Noteholders shall collectively receive a 10 year, assignable, freely transferable, 4% royalty

12

on the worldwide Net Sales (as defined therein) of GLOPERBA and ELYXYB, excluding sales of ELYXYB in Canada. Please see the section below